Xencor, Inc. (XNCR)
- Previous Close
23.76 - Open
23.88 - Bid 24.63 x 200
- Ask 24.92 x 200
- Day's Range
23.66 - 24.95 - 52 Week Range
16.49 - 27.62 - Volume
164,512 - Avg. Volume
654,855 - Market Cap (intraday)
1.526B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-2.17 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.27
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
www.xencor.comRecent News: XNCR
Performance Overview: XNCR
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XNCR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XNCR
Valuation Measures
Market Cap
1.47B
Enterprise Value
1.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.92
Price/Book (mrq)
2.39
Enterprise Value/Revenue
6.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-82.23%
Return on Assets (ttm)
-9.96%
Return on Equity (ttm)
-20.71%
Revenue (ttm)
162.18M
Net Income Avi to Common (ttm)
-133.36M
Diluted EPS (ttm)
-2.17
Balance Sheet and Cash Flow
Total Cash (mrq)
535.94M
Total Debt/Equity (mrq)
14.59%
Levered Free Cash Flow (ttm)
-5.88M